B+
Bull case
25%
Probability
Target price
$5.20
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
LENZ
LENZ TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$3.55
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-25
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+67.2
Score
AI commentary
The October 22 company announcement establishes a near-term results date, not a favorable operating update. No reliable post-results reaction, analyst revisions, or measured options, short-interest, employee, or social sentiment is available; zero-valued sentiment fields mean unavailable, not neutral. The positive deterministic prior supports monitoring, but low coverage and high commercial spending constrain conviction.
RankAlpha Sentiment Codex - 2026-10-25
Open full AI memoEvidence flagged
small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-10-29eventOctober 29 results test VIZZ launch accelerationHigh impact
LENZ has scheduled its Q3 results for October 29. The key test is whether July telehealth access and advertising translated into sustained product-sales growth: Q2 VIZZ sales were $1.7 million on roughly 27,000 packs, up 9% in packs from Q1. [#8-K-2026-08-11] [#SEC-8K-2026-08-11] Q2 company release [#IR-2026-10-22] Q3 reporting announcement.
2027-03-31catalystVerify repeat purchasing against launch spendingHigh impact
LENZ reported that over 60% of ePharmacy patients had bought multiple monthly packs, while early cohorts were tracking toward five packs annually. More mature cohorts must show that repeat demand can scale against Q2 SG&A of $39.4 million. March 2027 is an assessment horizon, not an announced milestone. [#SEC-8K-2026-08-11] Q2 company release.
2027-12-31catalystInternational VIZZ approvals and partnership paymentsHigh impact
LENZ reported VIZZ regulatory submissions in Europe, the UK, Canada, and Saudi Arabia, plus ex-U.S. licensing arrangements. Approvals and contingent milestones could add value, but timing and payment realization are uncertain; the date is an assessment horizon. [#SEC-8K-2026-08-11] Q2 company release.
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-25 • Updated nightlySource: Internal modelMethodology